Skip to main content
. 2021 Nov 8;35(12):3585–3588. doi: 10.1038/s41375-021-01466-0

Table 1.

Baseline demographics and clinical characteristics of patients infected by SARS-CoV-2 and association between these characteristics and mortality.

Characteristic Number (proportion) unless specified otherwise
Age, median age in years, (min–max) 57.7 (5.2–72.8)
Male sex 32 (57.1)
CAR T-cell therapy indication
  B-cell acute lymphoblastic leukemia 7 (12.5)
  B-cell non-Hodgkin lymphoma 46 (82.1)
  Multiple myeloma 3 (5.4)
Disease status at time of COVID-19 diagnosis
  Relapse/progression 14 (15)
  Partial response 7 (12.5)
  Complete remission 35 (62.5)
Metabolic comorbidities (obesity, hypertension, diabetes, hypercholesterolemia, smoking, and cardiovascular disease)
  Yes 18 (32.1)
  No 38 (67.9)
Lansky/Karnofsky-score at time of COVID-19 diagnosis
  <70 10 (17.9)
  ≥70 46 (82.1)
Oxygen therapy
  No oxygen support needed, 32 (57.1)
  Oxygen support needed 24 (42.9)
  Invasive mechanical ventilation 16 (28.6)
  Noninvasive ventilation (noninvasive positive pressure ventilation) 2 (3.6)
COVID-19 treatment
  Dexamethasone 10 (17.9)
  (Methyl)prednisolone 2 (3.6)
  Tocilizumab 8 (14.3)
  Baricitinib 2 (3.6)
  Eculizumab 1 (1.8)
  Remdesivir 20 (35.7)
  Lopinavir/Ritonavir 1 (1.8)
  Chloroquine/Hydroxychloroquine 1 (1.8)
  Convalescent plasma 17 (30.4)
  IVIG non-SARS-CoV-2 1 (1.8)
  Anticoagulants (either prophylaxis or treatment) 19 (33.9)
  No treatment 15 (26.8)
Resolution of COVID-19 in surviving patients
  Clinical resolution 10 (17.9)
  Virologic (PCR) resolution 21 (37.5)
  Clinical COVID-19 median duration, days (min–max) 20.0 (0–157)
  Virologic COVID-19 median duration, days (min–max) 48 (6–113)
Factors associated with mortality (HR, 95% CI, P value)
  Age at time of COVID-19 1.39 (1.05–1.86), p = 0.02
  Performance status at time of COVID-19 0.71 (0.56–0.89), p = 0.003
  Metabolic comorbidity 2.75 (1.19–6.35), p = 0.02
  Tumor not in complete remission at time of COVID-19 2.40 (1.04–5.55), p = 0.04